97 results about "Anti pd 1" patented technology

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.

This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. The present invention also provides immunoconjugates and pharmaceutical compositions comprising the antibodies or the functional fragments thereof according to the present invention. The present invention additionally provides methods for treating a plurality of diseases (comprising cancers, infectious diseases and inflammatory diseases) by using the antibodies or the functional fragments thereof disclosed herein.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., a B-cell cancer such as Hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.

The invention discloses an anti-PD-1 humanized monoclonal antibody and application thereof, belonging to the technical field of molecular immunology. The anti-PD-1 humanized monoclonal antibody provided by the invention contains a light chain and a heavy chain, wherein the amino acid sequence of the light chain is as shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain is as shown in SEQ ID NO.4 or SEQ ID NO.6. Meanwhile, the invention also provides a nucleotide sequence coding the light chain and heavy chain. The anti-PD-1 humanized monoclonal antibody provided by the invention has very high affinity with human PD-1 protein, and can interdict PD-1/PD-L1 combination so as to promote T cell proliferation and IFN-gamma secretion.

The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1: PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1-binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1-binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.

This provides pharmaceutical compositions that comprise a combination of an anti-cancer agent which is an first antibody and a second antibody. In some embodiments, the first antibody is an anti-Programmed Death-1 (PD-1) antibody. In certain embodiments, the composition is a fixed dose formulation. In certain embodiments, the composition is administered as a flat-dose. The disclosure also provides a kit for treating a subject afflicted with a disease, the kit comprising a dosage of any composition disclosed herein and instructions for using the composition in any of the disclosed methods for treating a disease.

The invention provides an antibody specifically combined with PD-1 (Programmed Death-1) with high affinity, and also provides a nucleic acid molecule for coding the antibody, an expression vector and a host cell for expressing the antibody, and a production method of the antibody. In addition, the invention also provides an immune conjugate and a medicinal composition containing the antibody, and application of the antibody to the preparation of a medicine for treating multiple diseases (including a cancer, an infectious disease and an inflammatory disease).

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) another anti-cancer agent. The other anti-cancer agent can be a platinum-based doublet chemotherapy, an EGFR-targeted tyrosine kinase inhibitor, bevacizumab, an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody, or any other therapy used to treat lung cancer in the art or disclosed herein.

This disclosure provides methods for treating Hodgkin's lymphoma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody. In some embodiments, this invention relates to methods for treating Hodgkin's lymphoma in a subject comprising administering to the subject a combination of an anti-cancer agent which is an anti-Programmed Death-1 (PD-1) antibody and another anti-cancer agent such as an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody.

The present disclosure provides novel anti-PD-1 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.

The invention relates to the technical field of biology, and in particular relates to an anti-PD-1 humanized antibody. The anti-PD-1 humanized antibody is characterized in that the amino acid sequence of a variable region of a heavy chain of the antibody is shown as SEQ ID NO: 2 or is a conserved variation sequence; the amino acid sequence of a variable region of a light chain of the antibody is shown as SEQ ID NO: 4 or is a conserved variation sequence. The anti-PD-1 humanized antibody shows relatively high expression quantity in mammalian cells, and is obvious in affinity with PD-1 and able to inhibit the combination of a ligand and a receptor.

The invention provides a method of treating a melanoma comprising (i) identifying a patient having a PD-L1 positive melanoma and (ii) administering to the patient an anti-PD-1 antibody or an antigen-binding portion thereof (“an anti-PD-1 antibody monotherapy”). The methods of the invention can extend progression-free survival for over 12 months and/or reduces the tumor size at least about 10%, about 20%, about 30%, about 40%, or about 50% compared to the tumor size prior to the administration.

The present invention relates to anti-PD1 and anti-CD19 bispecific antibody and applications thereof, wherein the anti-PD1 and anti-CD19 bispecific antibody, or a variant, or a functional fragment thereof comprises: a domain capable of specifically recognizing and binding an immune cell surface antigen PD-1, wherein the domain comprises the heavy chain variable region (anti-PD-1 VH) of an anti-PD-1 specific antibody; and a domain capable of specifically recognizing and binding CD19, wherein the domain comprises the heavy chain variable region (anti-CD19 VH) of an anti-CD19 specific antibody. According to the present invention, the bispecific antibody has the whole human sequence, such that the occurrence of HAMA in clinical treatment application is effectively avoided, the occurrence of drug resistance can be effectively reduced, and the utilization efficiency and the treatment effect of the medicine can be improved; and the anti-PD-1 and anti-CD19 bispecific antibody can well mediate T cells to efficiently and specifically kill B-lymphocyte derived tumor cells compared to the existing anti-PD-1 specific antibody and the existing anti-CD19 specific antibody.

The invention provides a monoclonal antibody against PD-1, especially a human monoclonal antibody against PD-1. The antibody specifically binds to PD-1 in virtue of high affinity and comprises a heavychain and a light chain. The invention also provides a nucleic acid sequence coding the antibody, a cloning or expression vector, a host cell, a method for expressing or isolating the antibody, and an immunoconjugate and therapeutic composition containing the antibody. The invention further provides application of the anti-PD-1 antibody to treatment of various cancers.

The invention belongs to the biotechnical field, and concretely relates to a recombinant humanized anti-PD-1 and c-MET bispecific antibody, and a preparation method and an application thereof. Humanized antibody database comparison, computer molecular structure simulation, molecular docking simulation and sequence analysis are carried out, and recombinant humanized anti-PD-1 and c-MET bispecific antibody molecule designing comprising affinity maturation, structure optimization, humanization and codon optimization is carried out, and an expression plasmid of the recombinant humanized anti-PD-1 and c-MET bispecific antibody is constructed on the basis of an optimized signal peptide sequence and a plasmid expression vector replicon. The bispecific antibody has the characteristics of low immunogenicity, simple and safe preparation process, high yield, high purity and high activity, and can be used to further prepare new specific drugs for treating non-small cell lung cancer.

The present invention provides stable pharmaceutical formulations comprising a human antibody that specifically binds to human programmed death-1 protein (PD-1). In certain embodiments, the formulations contain, in addition to an anti-PD-1 antibody, a buffer, an amino acid, a non-ionic surfactant, and a sugar. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability upon stress and storage.

Provided herein are methods of treating HPV-negative tumors comprising administering an effective amount of an antagonist of the PDL-1/PD-1 interaction (e.g., an anti-PDL-1 or anti-PD-1 antibody antigen binding fragment thereof).